+34 620 10 75 37info@nanbiosis.com

News

nanbiosis news

A dressing with active ingredients to regenerate skin wounds

Elisabeth Engel, Scientific Director of NANBIOSIS U5, Rapid Prototyping Unit, is interviewed in “Deuwatts”, a programe of  Btv, devoted to biomedical engineering. Dr. Engel explains how  they have designed a dressing with active substances to regenerate skin wounds and talks about bio-printing for therapeutic models.

Watch it here.

 

Read More

Agreements signed with MINECO for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, several projects related to the ICTS NANBIOSIS have been selected by the MINECO for co-financing with FEDER funds of the European Regional Development Funds program.

An agreement has been signed between MINECO and CIBER (partner of NANBIOSIS for the co-financing of the Project: “Purchase, installation and set-up of production and characterization equipment to complement the Units: U3-Synthesis of Peptides Unit, U18-Nanotoxicology and U20- In Vivo Experimental Platform”. The total budget of the project amounts to € 307,566.16, with 50% financing with FEDER Funds.

Also CSIC (The State Agency Superior Council of Scientific Investigations), institution that houses some of the NANBIOSIS units,  as distributed ICTS,  has signed an agreement with MINECO for the co-financing of the Project: “Purchase and installation and set-up of equipment and production and characterization laboratories to complement the units U2-Production of antibodies, U4-Biodeposition and biosensing, U6-Processing of biomaterials and U8-Micro, nanotechnology. The total budget of the project amounts to € 312.800,00 €, with 50% financing with FEDER Funds.

These two projects aim to increase the quantity and quality of the services offered by th implied units, with the objetive of positioning them as national and international benchmark in their respective fields of application. As a consequence, an increase in the performance (number of services and number of users) of each unit is expected, especially from companies (pharmaceutical and small biotechnology).

CSIC and CIBER are processing the necessary contracting procedures for the execution of these projects.

Read More

Adipose-Derived Stem Cells Ameliorates Ischemia-Reperfusion Injury in a Rat Skin Free Flap Model

Francisco Miguel Sánchez Margallo, Scientific Director of  CCMIJU and Javier García Casado, Scientific Director of NANBIOSIS U14, Cell Therapy Unit, are co-authors of the publication “Adipose-Derived Stem Cells Ameliorates Ischemia-Reperfusion Injury in a Rat Skin Free Flap Model”

The study was performed with the participation of the following NANBIOSIS Units: U21-Experimental operating rooms, U22-Animal housing, and U14-Cell Therapy

 

Article of reference: DOI: 10.1055/s-0038-1648246

Ballestín A, Casado JG, Abellán E, Vela FJ, Álvarez V, Usón A, Blázquez R, Sánchez-Margallo FM, J Reconstr Microsurg. 2018 May 3.  [Epub ahead of print]

 

Read More

DRIVE Project: Artificial Biopancreas for Type I Diabetics

On Saturday, June 2, in the auditorium of the Artium museum in Vitoria, a meeting was held for patients with diabetes, organized by the group of European researchers of the DRIVE project with the aim of conecting patiens with researchers.

The event was organized by the NanoBioCel research group of the CIBER-BBN and the University of the Basque Country, led by José Luis Pedraz, Scientific Director of   NANBIOSIS Unit 10, Drug Formulation, which participates, through the CIBER BBN and the ICTS Nanbiosis, in the Drive Project  focused on pancreatic  cell transplantation  and the development of biomaterials and new surgical devices that improve the transplantation and survival of insulin-producing pancreatic islets for the treatment of diabetes.

Dr. Pedraz explained for EIBT.eus Radio euskadi the aim of the DRIVE project: the transplantation of the cells of the pancreas, which consists of isolating the insulin-producing cells from a donor’s pancreas and implanting them in the patient with daibetes type I, not directly, but introduced into an artificial bio-pancreas by minimal invasive surgery . “Nowadays– explains Dr. Pedraz- obtaining pancreatic cells from stem cells or IPS cells is a not yet controlled process but it is an alternative source of insulin-producing cells. In the DRIVE project the most priority objective is to take the donor cells and introduce them into a device that will allow the patient to produce and release insulin in a more physiological way. In a second phase, it is intended to use differentiated insulin producing cells from the patient’s own cells, thus alleviating the shortage of  donors”.

Read More

Effect of Surface Chemistry and Associated Protein Corona on the Long-Term Biodegradation of Iron Oxide Nanoparticles In Vivo

The results of the research carried out by Scientists of U12. Nanostructured liquid characterization unit, and CIBER-BNN, have been published in an article by ACS Applied Materials & Interfaces:

DOI: 10.1021/acsami.7b18648

Read More

Relevant research results for assisted reproduction.

Javier García Casado, Scientific Director of NANBIOSIS Unit 14: Cell therapy toguether with other Scientists of NANBIOSIS and CCMIJU have issued the first report describing the beneficial effect of human EV-endMSCs on embryo development, which has been recently published by PloS One: “Murine embryos exposed to human endometrial MSCs-derived extracellular vesicles exhibit higher VEGF/PDGF AA release, increased blastomere count and hatching rates“.  The results could be relevant for assisted reproduction:

“Endometrial Mesenchymal Stromal Cells (endMSCs) are multipotent cells with immunomodulatory and pro-regenerative activity which is mainly mediated by a paracrine effect. The exosomes released by MSCs have become a promising therapeutic tool for the treatment of immune-mediated diseases. More specifically, extracellular vesicles derived from endMSCs (EV-endMSCs) have demonstrated a cardioprotective effect through the release of anti-apoptotic and pro-angiogenic factors. Here we hypothesize that EV-endMSCs may be used as a co-adjuvant to improve in vitro fertilization outcomes and embryo quality. Firstly, endMSCs and EV-endMSCs were isolated and phenotypically characterized for in vitro assays. Then, in vitro studies were performed on murine embryos co-cultured with EV-endMSCs at different concentrations. Our results firstly demonstrated a significant increase on the total blastomere count of expanded murine blastocysts. Moreover, EV-endMSCs triggered the release of pro-angiogenic molecules from embryos demonstrating an EV-endMSCs concentration-dependent increase of VEGF and PDGF-AA. The release of VEGF and PDGF-AA by the embryos may indicate that the beneficial effect of EV-endMSCs could be mediating not only an increase in the blastocyst’s total cell number, but also may promote endometrial angiogenesis, vascularization, differentiation and tissue remodeling”.

Soluble factors were analyzed by the ICTS Nanbiosis (Unit 14. Cell therapy at CCMIJU). Maintenance of animals was performed by the ICTS Nanbiosis (Unit 22. Animal housing at CCMIJU). In vivo embryo recovery and culture was performed by the ICTS Nanbiosis (Unit 23. Assisted Reproduction at CCMIJU)

Article of reference:

Blázquez R, Sánchez-Margallo FM, Álvarez V, Matilla E, Hernández N, Marinaro F, Gómez-Serrano M, Jorge I, Casado JG, Macías-García B. “Murine embryos exposed to human endometrial MSCs-derived extracellular vesicles exhibit higher VEGF/PDGF AA release, increased blastomere count and hatching rates”. PLoS One (2018-04; vol. 13(4))

DOI: 10.1371/journal.pone.0196080

Read More

20th European Conference on Integrated Optics

Prof Laura M. Lechuga, Scientific Director of NANBIOSIS U4 – Biodeposition and Biodetection Unit –  is part of the Organising Committee of the 2018 European Conference on Integrated Optics that will celebrate its 20th anniversary in Valencia from the 30th May to the 1st June 2018.  In the 2017 edition, which took place in Eindhoven, the conference featured more than two hundred attendees.

The conference focuses on leading edge research on integrated optics, optoelectronics and nano-photonics and gathers experts from academia and industry to show their latest technical results, and showcase their products and services.

The application scope is broad and it ranges from tele/datacom communications, optical interconnects, and (bio) optical sensing applications to more disruptive areas as quantum computing and mid-IR photonics.

 

 

ECIO 2018
Read More

NANBIOSIS participation at VII Conference of Young Researchers of I3A

The I3A organizes the VII Conference of Young Researchers to be held on June 2, 2018. As in past editions, the Confernce will be addressed to all those who are doing the doctoral thesis whose director or co-director is a member of I3A.

Scientists of  NANBIOSIS Unit 13 Tissue & Scaffold Characterization Unit will participate with the following poster:

Personalized simulation of intraestromal ring insertion surgery (ICRS). Validation with clinical data. Julio Flecha, Miguel Ángel Ariza-Gracia, Jesús Zurita, Begoña Calvo
Simulation of cell populations in Organ-On-Chip devices: of the models classics to data driven simulations. Jacobo Ayensa-Jiménez, Marina Pérez Aliacar, Teodora Randelovic, Sara Oliván, Iñaki Ochoa, Mohamed Hamdy Doweidar, Manuel Doblaré.

Read More

New frontiers in the treatment of Diabetes type 1

On Saturday, June 2, at 10.30 in the auditorium of the Artium Museum in Vitoria-Gasteiz, a meeting will take place for patients with diabetes, organized by the group of European researchers of the DRIVE project. The objective of the meeting, held for the first time in Spain, is to connect researchers with all those with diabetes and relatives who want to participate. “One of the objectives of this meeting is to better understand the expectations of people with diabetes and their doubts about the treatment of that disease. By giving us their opinion, they will help us to adapt the DRIVE project to their needs“, explained the organization.
The event is organized by the NanoBioCel research group of the University of the Basque Country / Euskal Herriko Unibertsitatea, directed by José Luis Pedraz, Scientific Director of NANBIOSIS Unit 10, Drug Formulation, who participates in the DRIVE project through the CIBER BBN and the ICTS Nanbiosis, the only Spanish group in the project .
Admission is free and can be obtained at: https://www.ticketea.com/entradas-conferencia-drive-patient-panel/

 

Read More

FORUM ON NANOMEDICINE APPLICATIONS IN DRUG DELIVERY AND TARGETING

ICTS Nanbiosis, together with Nanomed Spain has organized a forum with companies on NANOMEDICINE APPLICATIONS IN DRUG DELIVERY AND TARGETING that will take place next June 21 in Barcelona (Barcelona School of Management, Universitat Pompeu Fabra – C / Balmes, 132-134)

The forum will be presented through 2 sessions:
1- Short interventions of the latest advances and developments in the research lines developed by the groups and NANBIOSIS Units and description of the needs and demands of the industry in that area.
2- Bilateral meetings of about 15 minute company-group / NANBIOSIS Unit to identify possible collaborations.

The event will include the participation of the CDTI that will present the CDTI Financing Instruments for the use of Singular Scientific Technical Facilities and public-private collaboration

Registration is free and will be by order of registration until the capacity is exhausted.

Program and registration

Read More